How should a patient suspected of having Ehlers‑Danlos syndrome be evaluated and managed?

Evaluation and Management of Suspected Ehlers-Danlos Syndrome

A patient suspected of having Ehlers-Danlos syndrome requires clinical diagnosis based on the triad of joint hypermobility, skin hyperelasticity, and tissue fragility, followed by genetic testing to exclude alternative diagnoses and confirm specific subtypes—except for hypermobile EDS (hEDS), which remains a clinical diagnosis after genetic exclusion.

Diagnostic Approach

Initial Clinical Assessment

The diagnostic evaluation centers on identifying three cardinal features 1, 2:

• Joint hypermobility using standardized scoring (Beighton criteria)
• Skin hyperelasticity (soft, velvety, or hyperextensible skin)
• Tissue fragility (easy bruising, atrophic scarring, poor wound healing)

For hEDS specifically, you must fulfill all three criteria 3:

1. Generalized joint hypermobility (GJH) documented by Beighton score
2. Musculoskeletal manifestations (chronic joint pain, recurrent dislocations) plus systemic features consistent with connective tissue disorder
3. Exclusion of alternative diagnoses through genetic testing

Critical Role of Genetic Testing

Genetic testing is essential and frequently reveals alternative diagnoses even in patients who appear to meet hEDS criteria 3. In one cohort of 178 patients meeting 2017 hEDS diagnostic criteria, genetic testing identified an alternative or additional diagnosis in 26.4% (47 patients), requiring distinct management strategies 3.

The genetic evaluation should 4:

• Test for the 12 known EDS subtypes with identified genetic mutations
• Screen for other connective tissue disorders, inflammatory diseases, and chromosomal abnormalities that present with hypermobility 3
• Consider skin biopsy with electron microscopy when genetic testing direction is unclear 4

A common pitfall is diagnosing hEDS without adequate genetic exclusion of other subtypes, particularly vascular EDS (vEDS), which carries life-threatening complications 4.

Screening for Comorbid Conditions

Autonomic Dysfunction Evaluation

Do not perform universal autonomic testing in all hEDS patients 5. Instead, target screening to those with specific orthostatic symptoms 5:

• Palpitations, dizziness, presyncope, or syncope upon standing
• Symptoms that improve when sitting or lying down
• Exacerbation with food ingestion, physical exertion, or heat exposure
• Refractory GI symptoms despite lifestyle modifications

Refer for formal autonomic testing only after excluding medication side-effects and attempting conservative measures 5.

Gastrointestinal Evaluation

For patients with GI symptoms, follow this algorithmic approach 6:

Early diagnostic testing:

• Consider celiac disease screening earlier than in general population (not limited to diarrhea presentations) 6
• Perform anorectal manometry, balloon expulsion test, or defecography for incomplete evacuation symptoms, given high prevalence of pelvic floor dysfunction and rectal hyposensitivity 6
• Measure gastric emptying and accommodation in patients with comorbid POTS and chronic upper GI symptoms 6

Mast cell activation syndrome (MCAS) screening should be considered when 6:

• Episodic symptoms suggest generalized mast cell disorder beyond GI tract
• Symptoms span multiple organ systems or mimic allergic reactions
• Testing involves baseline serum tryptase and repeat measurement 1–4 hours following symptom flares (diagnostic threshold: 20% increase above baseline plus 2 ng/mL) 6
• If MCAS is supported, refer to allergy specialist or mast cell disease research center 6

Oral and Maxillofacial Examination

Subtype-specific features can aid diagnosis 7:

• Nasal bridge depression (80% of arthrochalasia EDS)
• Downslanting palpebral fissures (80% of kyphoscoliotic EDS)
• Deep-set eyes (34% of classical EDS)
• Tooth agenesis, pulpal calcifications, root fusion, or gingival hyperplasia

Management Strategy

Non-Pharmacologic First-Line Interventions

Management is symptomatic and multidisciplinary, with no disease-modifying treatments available for non-vascular EDS 1, 2.

For confirmed POTS/autonomic dysfunction 5:

• Fluid and salt optimization: Substantially increase daily fluid intake with liberalized dietary sodium
• Structured exercise training: Supervised cardiovascular fitness programs maintaining conditioning despite symptoms
• Compression garments: Stockings or abdominal binders to reduce venous pooling

For GI symptoms, follow DGBI management principles with 6:

• Avoidance or cessation of opioids in pain-predominant features
• Brain-gut behavioral therapies for anxiety and psychological distress
• Symptom-focused supportive care

Nutritional Considerations

Patients commonly have inadequate nutrient intake 8:

• High protein (77.2g), high fat (79.1g) diets that are low in calories, Vitamin B, D, and fiber
• Only 24.7% achieve fiber requirements
• Four dietary patterns exist, with "low food intake" pattern showing highest nutrient inadequacy and ARFID scores 8
• Dietetic consultation is underutilized but should be considered, especially for restrictive eating patterns 8

Pharmacologic Treatment

Reserve pharmacologic therapy for moderate-to-severe functional impairment after failure of conservative measures, requiring coordinated care among cardiology, neurology, and gastroenterology 5.

Critical Caveats

• Vascular EDS requires urgent identification due to life-threatening arterial and organ rupture risk 4
• Many studies apply inconsistent 2017 hEDS diagnostic criteria, affecting prevalence estimates 5
• Medications (stimulants, centrally acting agents) may confound autonomic testing 5
• The molecular basis of hEDS remains unknown, limiting mechanistic understanding 5, 3
• Clinical decision-making relies on limited research evidence, with no high-quality clinical practice guidelines currently available 9